Aligos therapeutics presents program updates at the 32nd conference of the asian pacific association for the study of the liver

South san francisco, calif., feb. 16, 2023 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in nash and viral diseases, today announced that the company is delivering several oral and poster presentations at the 32nd conference of the asian pacific association for the study of the liver (apasl), being held feb 15 – 19 in taipei, taiwan at the taipei international convention center. data is being presented for alg-055009, aligos' thr-Β agonist in clinical development for nonalcoholic steatohepatitis (nash), as well as for several clinical and nonclinical stage investigational agents from its chronic hepatitis b (chb) portfolio.
ALGS Ratings Summary
ALGS Quant Ranking